UroGen Pharma
URGN
43 hedge funds and large institutions have $454M invested in UroGen Pharma in 2018 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 21 increasing their positions, 7 reducing their positions, and 8 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 7
78% more capital invested
Capital invested by funds: $254M → $454M (+$200M)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
8.16% more ownership
Funds ownership: 51.88% → 60.04% (+8.2%)
5% more funds holding
Funds holding: 41 → 43 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MMH
Menora Mivtachim Holdings
Ramat Gan,
Israel
|
+$26.8M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$21.1M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$20.2M |
| 4 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
+$14M |
| 5 |
CCM
Consonance Capital Management
New York
|
+$11.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$7.41M |
| 2 |
SIM
Spark Investment Management
New York
|
-$2.63M |
| 3 |
LCM
Laurion Capital Management
New York
|
-$1.77M |
| 4 |
LSC
Lyon Street Capital
Sausalito,
California
|
-$1.19M |
| 5 |
HCM
Highline Capital Management
New York
|
-$1.16M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$11K | -300 | Closed |
|
URGN Hedge Fund Activity: Q1 2018 in Review
43 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q1 2018, worth a combined $454M — up 78% from $254M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new URGN positions and 8 closed out — a net gain of 2 holders — while 21 added to existing stakes and 7 trimmed.
The largest buyer was Menora Mivtachim Holdings, adding an estimated $26.8M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $7.41M sold.
- 43 institutional investors held UroGen Pharma (URGN) as of Q1 2018, up from 41 in Q4 2017.
- Funds reported $454M of UroGen Pharma stock for Q1 2018, up 78% quarter-over-quarter.
- 10 funds opened new UroGen Pharma positions in Q1 2018 and 8 closed out, a net change of +2 holders.
- The largest UroGen Pharma buyer in Q1 2018 was Menora Mivtachim Holdings, an estimated $26.8M added.
- The largest UroGen Pharma seller in Q1 2018 was Perceptive Advisors, an estimated $7.41M sold.
Based on aggregated 13F filings for Q1 2018.